Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Free Radic Biol Med. 2021 Feb 17;166:73–89. doi: 10.1016/j.freeradbiomed.2021.02.006

Figure 12.

Figure 12.

Effects of KYC Treatment on KYC Thiylation of Keap1, Keap1 S-Glutathionylation and Nrf2 Activation in Lungs of Hyperoxic Pups. (A) The streptavidin affinity-blot for B-KYC-thiylated Keap1 and the immunoblot for Keap1 show that KYC treatment increased B-KYC-thiylation of Keap1 in lung lysates from hyperoxic pups. The bar chart shows the mean ± SD of the relative levels of B-KYC-thiylated Keap-1 as a function to Keap1 in lung lysates of hyperoxic pups treated with PBS and KYC. These data show that KYC treatment increased KYC thiylation of Keap1 in the lungs of hyperoxic pups. (B) Immunoblot for S-glutathionylated Keap1 shows that KYC treatment increased Keap1 S-glutathionylation in lung lysates from hyperoxic pups. The bar chart shows the mean ± SD of the relative levels of GS-thiylated Keap-1 as a function to Keap1 in lung lysates of hyperoxic pups treated with PBS and KYC. These data show that KYC treatment increased S-glutathionylated Keap1 (GS-Keap1) in the lungs of hyperoxic pups. (C) The immunoblot shows the relative levels of Nrf2 in lung lysates from normoxic pups treated with PBS and KYC. The bar chart shows the mean ± SD of the relative levels of Nrf2 as a function to actin in lung lysates of normoxic pups treated with PBS and KYC. These data show that KYC treatment increased Nrf2 activation in lungs of normoxic pups. (D) Representative immunoblots of relative levels of Nrf2 activation in lung lysates from hyperoxic pups treated with PBS and KYC. The bar chart shows the mean ± SD of the relative levels of Nrf2 as a function of actin in lung lysates of hyperoxic pups treated with PBS and KYC. These data show that KYC treatment increased Nrf2 activation in lungs of hyperoxic pups.